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Introduction: Cell therapy is a potential therapeutic approach for neurodegenerative disorders, such as Alzheimer
disease (AD). Neuronal differentiation of stem cells before transplantation is a promising procedure for cell therapy.
However, the therapeutic impact and mechanisms of action of neuron-like cells differentiated from human
umbilical cord mesenchymal stem cells in AD have not been determined.
Methods: In this study, we used tricyclodecan-9-yl-xanthogenate (D609) to induce human mesenchymal stem cells
isolated from Wharton jelly of the umbilical cord (HUMSCs) to differentiate into neuron-like cells (HUMSC-NCs), and
transplanted the HUMSC-NCs into an AβPP/PS1 transgenic AD mouse model. The effects of HUMSC-NC
transplantation on the cognitive function, synapsin I level, amyloid β-peptides (Aβ) deposition, and microglial
function of the mice were investigated.
Results: We found that transplantation of HUMSC-NCs into AβPP/PS1 mice improved the cognitive function,
increased synapsin I level, and significantly reduced Aβ deposition in the mice. The beneficial effects were
associated with “alternatively activated” microglia (M2-like microglia). In the mice transplanted with HUMSC-NCs,
M2-like microglial activation was significantly increased, and the expression of antiinflammatory cytokine associated
with M2-like microglia, interleukin-4 (IL-4), was also increased, whereas the expression of proinflammatory cytokines
associated with classic microglia (M1-like microglia), including interleukin-1β (IL-1β) and tumor necrosis factor-α
(TNF-α), was significantly reduced. Moreover, the expression of Aβ-degrading factors, insulin-degrading enzyme
(IDE) and neprilysin (NEP), was increased substantially in the mice treated with HUMSC-NCs.
Conclusions: HUMSC-NC transplantation decreased Aβ deposition and improved memory in AβPP/PS1 mice
by a mechanism associated with activating M2-like microglia and modulating neuroinflammation. Transplantation
of neuron-like cells differentiated from mesenchymal stem cells might be a promising cell therapy for
Alzheimer disease.
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Alzheimer disease (AD) is an age-related progressive
neurodegenerative disorder. The major symptoms of AD
include memory loss and severe cognitive decline.
Pathology of the AD brain is characterized by amyloid
plaques, neurofibrillary tangles, and neuronal loss. Ele-
vated amyloid β-peptide (Aβ) deposition is the key
pathogenic factor for AD and the main cause for neu-
ronal loss in AD [1]. Thus, promising therapeutic stra-
tegies for AD aim to prevent, reverse, and reduce Aβ
deposition [2].
Cell therapy is a potential therapeutic approach for
neurodegenerative disorders, such as AD [3,4]. It has
been found that transplantation of cells isolated from
human umbilical cord, mesenchymal stem cells (MSCs),
or neural progenitor cells improves neuropathology in
animal models of AD through modulation of neuro-
inflammation [5-8]. Recently, a number of studies dem-
onstrated that transplantation of neuronal cells induced
from MSCs produces beneficial effects in neurodegener-
ative diseases and spinal cord injury [9-11]. It has been
shown that neuronal cells differentiated from human
MSCs are more resistant to Aβ42 oligomer-induced cyto-
toxicity than are undifferentiated cells [12]. Thus, neur-
onal differentiation before transplantation could yield
better efficacy than transplantation of undifferentiated
MSCs in clinical application.
The mechanism underlying the beneficial effects of
stem cell transplantation on neurodegenerative diseases
has been found to be associated with microglial function
in brain. Microglia, the mononuclear phagocytes of
brain, accumulate in senile plaques in AD patients and
in animal models of AD. It has been shown that mi-
croglia release proinflammatory cytokines, such as tu-
mor necrosis factor-α (TNF-α), interferon-γ (IFN-γ),
interleukin-1β (IL-1β), and NO, causing neurodegene-
ration [13]. In contrast, growing evidence has also sup-
ported that “alternatively activated” microglia (M2-like
microglia) play protective roles in AD by phagocytizing
Aβ and secreting neurotrophic cytokines [14]. Multiple
studies demonstrated that intracerebral transplantation
of MSCs increases M2-like microglial activation, regu-
lates neuroinflammation, and reduces Aβ deposits in AD
mouse models [8,9,15].
In this study, we used tricyclodecan-9-yl-xanthoge-
nate (D609) to induce HUMSCs to differentiate into
neuron-like cells (HUMSC-NCs) and transplanted the
HUMSC-NCs into an AβPPswe/PS1dE9 mouse model
of AD. We found that transplantation of HUMSC-
NCs reduced Aβ deposition in the mouse and im-
proved the mouse’s cognitive function. The beneficial
effects might be associated with M2-like microglial
activation and modulation of neuroinflammation by
HUMSC-NC transplantation.Materials and methods
Animals
The heterozygous AβPPswe/PS1dE9 double-transgenic
mouse with C57BL/6 background was used in this study.
The mouse harbors the mutant human genes APPswe
(Swedish mutations K594N/M595L) and presenilin-1
with the exon-9 deletion (PS1-dE9) under the control of
mouse prion protein promoter. This type of transgenic
mouse has been used widely in the study of AD [16,17].
The mouse shows typical characteristics of AD and ex-
hibits an early appearance of amyloid plaques deposition
and increased proinflammatory microglial activation
[17,18]. Because of the gender-specific differences in the
progression of amyloid plaque deposition, we used only
male mice in this study. The mice were obtained from
Beijing HFK Bio-Technology Co., Ltd., Institute of La-
boratory Animal Science, Chinese Academy of Medical
Science (Beijing, China), and housed in temperature-
and humidity-controlled rooms on a 12 hour/12 hour
light/dark cycle. Breeder mice carrying the transgenes
are backcrossed to the C57BL/6 strain for six to seven
generations to obtain mice used in research. The mice
are genotyped to confirm the presence of the mutant
genes by polymerase chain reaction (PCR) amplification
of genomic DNA extracted from tail clippings before the
mice are sold to research laboratories. All the pro-
cedures described in this study were in accordance
with the Ethical Committee for Animal Experiments
of Shandong University.
HUMSC isolation and in vitro culture
Human umbilical cords were obtained from full-term
deliveries with the informed consent from parents after
caesarian section. The procedure for collecting tissues
was approved by the ethical committee of the Second
Hospital of Shandong University. The procedure was
based on the previous description by Huang et al. [19].
After arteries and veins were removed, the remaining
tissue, Wharton jelly, was cut into 0.5- to 1-cm3 pieces
and suspended in Dulbecco modified Eagle low-glucose
media (DMEM-LG; Gibco, Grand Island, NY, USA)
containing 10% fetal bovine serum (FBS; Gibco), 100
mg/ml penicillin, and 100 mg/ml streptomycin. The tis-
sue was left undisturbed for 7 days in a 37°C humidified
incubator with 5% CO2 to allow cells to migrate from
the explants. Culture media was replaced every 3 days.
The cells were passaged by using 0.25% trypsin-EDTA
solution when they reached 80% to 90% confluence. The
cells were analyzed with flow cytometry to confirm the
immune-phenotype of HUMSCs according to the previ-
ous report [20]. The cells used in this study were posi-
tive for CD73, CD90, and CD105, but negative for
CD34, CD45, and HLA-DR, consistent with HUMSC
characteristics.
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After HUMSCs were passaged 2 to 6 times and reached
subconfluence, the cells were washed twice with basal
DMEM media (without FBS) and divided into two
groups. In the control group, the cells were cultured in
basal DMEM medium (without FBS); in the D609 treat-
ment group, the cells were cultured in basal media con-
taining 60 μg/ml D609 (J&K, Beijing, China) to induce
neuronal differentiation. D609 was prepared freshly in
deionized water. We determined the optimal working
concentration of D609 by performing a dose response
of HUMSCs to 2 to 100 μg/ml of D609, and we
found that 60 μg/ml D609 was the optimal concentra-
tion for neuronal differentiation (data not shown).
The morphology of cells was observed under a phase-
contrast microscope.
Immunocytochemistry
To determine the expression of neuronal cell markers,
HUMSCs grown on glass coverslips were treated with
D609 or basal medium for 6 hours. The cells were fixed
in 4% paraformaldehyde in phosphate-buffered saline
(PBS) for 20 minutes and then washed 3 times with PBS.
The cells were blocked with normal goat serum for 20
minutes at room temperature and then incubated in the
following primary antibodies: neuron-specific enolase
(NSE, rabbit IgG, 1:200, Abcam, Cambridge, MA, USA),
microtubule-associated protein 2 (MAP2, rabbit IgG,
1:200, Abcam), and glial fibrillary acidic protein (GFAP;
rabbit IgG, 1:200, Sigma, St Louis, MO, USA). The cells
were then washed in PBS and incubated with the sec-
ondary antibodies (goat anti-rabbit IgG-TRITC) for 1
hour at room temperature. After washing with PBS, the
cells were observed under a fluorescence microscope
(Olympus 1 × 71S1F-3, Tokyo, Japan). The differenti-
ation rate of HUMSCs was calculated according to the
following formula: The differentiation rate (percentage) =
(the number of NSE or MAP2 positive cells/the total
number of cells) ×100. For each sample, 10 randomly
selected visual fields were used for the calculation. The
results presented are the mean ± SEM from three inde-
pendent experiments.
Transplantation of HUMSC-NCs in AβPP/PS1
double-transgenic mice
HUMSC-NC suspension, HUMSC suspension, or PBS
was injected into 6-month-old male AβPP/PS1 trans-
genic mice for only one time. Before the injection, the
cell suspension was washed with PBS for 3 times to re-
move drug and serum. Animals were anesthetized with
10% chloral hydrate and placed in a small animal stereo-
taxic apparatus with a microinjector unit. Either cell
suspension or PBS was injected into mouse bilateral
hippocampus at the following coordinates: 1.6 mmposterior to the bregma, 1.7 mm bilateral to the midline,
and 2.5 mm ventral to the skull surface. Cell suspension
was injected with a 25-μl syringe. Then 2 μl of cell sus-
pension (approximately 5 × 104 cells) was injected into
the hippocampus bilaterally. Cell suspension or PBS
was delivered at a rate of 0.3 μl/min. After injection,
the needle was left in place for 5 minutes before be-
ing retracted.
Behavior test
Three weeks after transplantation, we used the modified
Morris water-maze test to assess spatial memory per-
formance [21]. The procedure consisted of 1 day of
adapting tests without platform and 5 days of hidden-
platform tests, plus a spatial probe test 24 hours after
the last hidden-platform test; 15 mice were used in each
group. The detailed method was described in our previ-
ous report [22]. In brief, in the spatial-acquisition tests,
mice were released into the pool and given 60 seconds
to find the hidden platform. If a mouse did not find the
platform within 60 seconds, it was guided to the plat-
form. Animals were given four trials per day. The distal
starting positions were semirandomly selected. For basic
acquisition training, the platform was located in the
southwest quadrant. The starting positions were north,
east, southeast, and northwest. The time to find the plat-
form was recorded as the latency for each trial. A single
probe trial, in which the platform was removed, was
performed after the hidden-platform task had been
completed. Mice were placed in a novel start position
(northeast) in the maze, and each mouse was allowed
to swim for 60 seconds. The data were analyzed with
multivariate analysis of variance (ANOVA). Mouse be-
havior was observed blindly. Observers were kept ig-
norant of the treatment given to each animal group.
Thioflavin S staining and immunohistochemical staining
AβPP/PS1 mice were killed after the behavior test. The
mice were anesthetized with chloral hydrate, and then were
immediately cardiac perfused with 0.9% saline solution
followed by 4% paraformaldehyde in 0.1 M PBS (pH 7.4).
After the perfusion, the brains of the mice were excised and
postfixed overnight at 4°C. The brain tissue was then
incubated in 30% sucrose at 4°C until equilibration (six
mice per group). Then 30- or 10-μm coronal sections were
cut with a freezing microtome (Leica CM1850, Leica
Microsystems, Heidelberg Germany) and stored at −20°C.
Thioflavin S staining was performed on floating sections
(30-μm thickness). Brain sections were incubated in 0.5%
thioflavin S (Sigma-Aldrich, USA) dissolved in 50% ethanol
for 5 minutes, and then washed twice with 50% ethanol for
5 minutes each time. The brain sections were washed once
with tap water for 5 minutes, and then mounted with
mounting medium [8]. The green fluorescence-stained
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Frontal cortex, cingulate, and hippocampus were examined
for amyloid load. According to the previous report [23],
these regions have plaque prevalence in AD patients
and are involved in memory functions.
For immunohistochemical staining, frontal cortex and
hippocampus sections (10-μm thickness) were incubated
with primary antibody at 4°C overnight. The following
primary antibodies were used: Iba-1 (rabbit IgG, 1:500,
Wako, Richmond, VA, USA); IL-4 (goat IgG, 1:200,
Santa Cruz, Dallas, Texas, USA); TNF-α (goat IgG,
1:200, Santa Cruz); AMCase, (goat IgG, 1:200, Santa
Cruz). Fluorescent dye-conjugated secondary antibodies
(IgG-FITC or IgG-TRITC) were used to visualize the
staining. To quantify the IHC staining, 10 serial cortex
and hippocampal sections (at an interval of 50 μm for
each section) from each animal (n = 6 for each group)
were used to quantify each parameter. The staining was
analyzed with the image-analyzing system, Image Pro
Plus 6 (Media Cybernetics, Rockville, MD, USA).
Western blot analysis
Cerebral cortex and hippocampus from one hemisphere
were isolated from AβPP/PS1 mice of each group after
the behavior test (six mice per group). Brain tissue sam-
ples were snap frozen and stored at −80°C for future
experiment. The brain samples were homogenized in
ice-cold RIPA lysing buffer (Beyotime, Shanghai, China).
The homogenized samples were centrifuged at 12,000 g
for 20 minutes at 4°C. The supernatant was collected
for Western blot. The proteins were separated with
SDS-PAGE and transferred to PVDF membranes. The
membranes were blocked with 5% nonfat dry milk in
TBST for 1 hour and incubated with primary antibodies
overnight at 4°C. The following primary antibodies were
used: Synapsin I (rabbit IgG, 1:1,000, Abcam), NEP
(goat IgG, 0.2 μg/ml, R&D, Minneapolis, MN, USA);
IDE (rabbit IgG, 1:5,000, Abcam); and β-actin (mouse
IgG, 1:400, Santa Cruz) [22]. The following secondary
antibodies were used: goat anti-mouse IgG/HRP
(1:5,000, Golden Bridge International, Beijing, China);
goat anti-rabbit IgG/HRP (1:5,000, Golden Bridge Inter-
national); rabbit anti-goat IgG/HRP (1:5,000, Golden
Bridge International). The intensity of the bands was
quantified by using Image J software developed by
Wayne Rasband, National Institutes of Health,
Bethesda, MD, USA.
Aβ ELISA
Aβ40 and Aβ42 enzyme-linked immunosorbent assays
(ELISAs) were performed by using ELISA kits
(Invitrogen, Carlsbad, CA, USA). Aβ standards (1 to 40
or 1 to 42 aa) were used according to the manufacturer’s
manual. Hippocampus and cortex from one hemispherewere homogenized in eight volumes of ice-cold guan-
idine buffer (5.0 M guanidine-HCl 50 mM Tris–HCl, pH
8.0) (six mice per group). The homogenate was incu-
bated at room temperature for 4 hours and diluted at
1:20 with ice-cold reaction buffer BSAT-DPBS (Dulbecco
phosphate-buffered saline, with 5% BSA, 0.03% Tween-
20, 0.2 g/L KCl, 0.2 g/L KH2PO4, 8.0 g/L NaCl, 1.150 g/L
Na2HPO4, pH7.4) containing 1 × Protease Inhibitor
Cocktail (PMSF, aprotinin, leupeptin, EDTA, pepstatin A,
NaF, and NaVO3), and then was centrifuged at 15,000 g
at 4°C for 20 minutes. The supernatant was used for
ELISA assay.
Quantitative real-time PCR
Total RNA from cortex and hippocampus of one hemi-
sphere was extracted by using Trizol (Invitrogen) according
to the manufacturer’s protocol (six mice per group); 1 μg
total RNA was used for reverse transcription in a final vol-
ume of 20 μl. Reverse transcription was performed
according to the manufacturer’s protocol (DRR047A,
Takara, Otsu, Shiga, Japan). Then 2 μl cDNA was used for
real-time PCR with the SYBR Premix Ex Taq (DRR041A,
Takara, Japan). Quantitative real-time PCR was performed
under the following conditions: 95°C for 30 seconds, 95°C
for 5 seconds, 60°C for 34 seconds, and 40 cycles. All PCR
reactions were performed in triplicate. The fold changes of
target genes were calculated by using the delta delta cycle
threshold (two delta delta CT) method [24]. GAPDH was
used as the reference gene. The PCR primers used in the
study were reported previously [8].
Statistical analysis
All data were presented as mean ± standard error of the
mean (SEM). Differences were analyzed with ANOVA. A
value of P < 0.05 was considered statistically significant.
In two-variable experiments, two-way ANOVA followed
by Bonferroni post hoc tests were used to analyze the
significance of differences between groups. One-way
ANOVA was used to analyze one-variable experiments
with three groups. The Student t test was used to compare
two groups. Data were analyzed with the software SPSS
16.0 (SPSS Inc., Chicago, IL, USA).
Results
D609 induces neuron-like differentiation of HUMSCs
Wang and colleagues found that D609 can induce rat
MSCs and human bone marrow stem cells to differenti-
ate into neuron-like cells within 6 hours. Thus, we ex-
amined the morphologic change and the expression of
neuronal markers of HUMSCs after 6-hour treatment
with D609. HUMSCs appeared as large and flat cells in
the absence of D609 treatment. After 6 hours of D609
treatment, most of the cells exhibited a typical neuron-
like morphology characterized by a multipolar cell body
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formed a connected network; no obvious morphologic
change was found in the control group (HUMSCs,
Figure 1A). Immunocytochemistry analysis showed
that HUMSC-NCs expressed high levels of the neur-
onal cell markers, neuron-specific enolase (NSE) and
microtubule-associated protein 2 (MAP2) (Figure 1B).
The percentage of cells expressing NSE or MAP2 was
86.42% ± 6.787% or 82.39% ± 5.644% in the D609-treated
group. However, in the control groups, HUMSCs ex-
pressed NSE or MAP2 weakly (Figure 1B). To examine
further the quality and quantity of the neuronal differenti-
ation, we examined the expressions of glial fibrillary acidic
protein (GFAP), a marker for glial cells, in the D609-
induced cells. We did not find GFAP expression in the dif-
ferentiated cells, indicating that D609 induces HUMSCs
to differentiate into neuron-like cells but not glial cells
(see Additional file 1: Figure S1).
HUMSC-NC transplantation improves spatial learning and
alleviates memory impairments in AβPP/PS1 mice
To determine the effect of HUMSC-NC transplantation
on the behavior of AβPP/PS1 mice, we used a Morris
water maze to examine the spatial learning and memoryFigure 1 Neuron-like cell differentiation from HUMSCs by D609 induc
by an inverted phase-contrast microscopy. Scale bar, 50 μm. (B) Immunocy
in HUMSCs and HUMSC-NCs. Cells were fixed and stained with rabbit anti-
Fluorescent dye-conjugated secondary antibody, goat anti-rabbit IgG-TRITC
The images were captured with a camera system connected to a fluoresceof the mice 3 weeks after they received HUMSC-NC,
HUMSC, or PBS injection. No difference in behavioral
performance was detected in the HUMSC-treated mice
compared with the PBS-treated mice. However, the mice
treated with HUMSC-NCs performed significantly better
in the water-maze test than did the mice treated with
PBS. The mean escape latency of the mice treated
with HUMSC-NCs was significantly shorter than that
of the mice treated with PBS (2A). We evaluated
mouse spatial memory by performing probe trials 24
hours after the last training session. The number of
platform location crosses and the time spent in the
target quadrant of the mice treated with HUMSC-
NCs was significantly higher and longer than were
those of the mice treated with PBS (Figure 2B, C).
The swimming speed was not significantly different
among the three groups (Figure 2D), suggesting that
the improved behavioral performance of the mice
treated with HUMSC-NCs was caused by cognitive
processes but not noncognitive components of beha-
vior. Thus, our data suggest that single intracerebral
injection of HUMSC-NCs alleviates learning deficits
and memory impairments in AD mice, whereas single
injection of HUMSCs does not.tion. (A) Representative images of HUMSCs and HUMSC-NCs obtained
tochemistry staining for neuronal markers NSE (red) and MAP2 (red)
human NSE IgG (1:200) or rabbit anti-human MAP2 IgG (1:200).
, was used to visualize the cells. Nuclei were stained with DAPI (blue).
nce microscope (Olympus 1x71S1F-3, Japan). Scale bar, 50 μm.
Figure 2 HUMSC-NC transplantation improved spatial learning and alleviated memory impairments in AβPP/PS1 mice. (A) HUMSC-NC
transplantation improved spatial learning in AD mice. Spatial learning was measured as escape latencies per day. Fifteen mice were used in each
group. (B, C) HUMSC-NC transplantation restored spatial memory in the AD mice. Mouse spatial memory was evaluated by the number of
platform location crosses (B) and the time spent in the target quadrant (C). (D) Swimming speed was not significantly different between groups.
Data are presented as mean ± SEM; *P < 0.05, **P < 0.01, HUMSC-NC-treated group versus PBS-treated group.
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The cognitive impairment in AD is associated mostly
with synaptic loss and dysfunction. Synapsin I has been
shown to play a key role in functional maturation of
synapse and neurotransmitter release [25]. We then
compared the expression of synapsin 1 protein in the
hippocampus between HUMSC-NC-transplanted and
PBS-treated mice. We found that synapsin I protein ex-
pression in hippocampus was increased significantly inFigure 3 HUMSC-NC transplantation increased synapsin I level. (A) Re
hippocampus. (B) Quantification of the Western blot for synapsin I. The de
control β-actin. The percentage of the expressions of synapsin I in the HUM
group was then calculated. The scanned image of Western blot was analyz
*P < 0.05, HUMSC-NC-treated group versus PBS-treated group.HUMSC-NC-transplanted mice compared with that in
PBS-treated mice (Figure 3), suggesting that the cogni-
tive improvement in HUMSC-NC-treated mice might be
associated with the upregulation of synapsin 1.
HUMSC-NC transplantation significantly reduces Aβ
deposition and decreases soluble Aβ levels
Aβ deposition is the key pathogenic factor for AD and
causes cognitive deficits. We investigated the effect ofpresentative Western blots for synapsin I protein expression in
nsitometry of synapsin I bands was first normalized to the loading
SC- or HUMSC-NC-treated group relative to that in the PBS-treated
ed with the software Image J. Data were presented as mean ± SEM.
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mice. We used thioflavin S staining to determine Aβ
deposition. We found that Aβ deposition in both the
cortex and hippocampus of the mice treated with
HUMSC-NCs was dramatically reduced compared with
that of the mice treated with PBS (Figure 4A, B). Be-
cause Aβ can be released by cleavage of a99-residue C-
terminal fragment (CTF), we measured the CTF level in
the cortex or hippocampus of the mice with Western
blot. No difference in the CTF level was found among
the three groups (data not shown), indicating that
HUMSC-NC transplantation does not affect Aβ produc-
tion. Further to confirm the reduction of Aβ depositionFigure 4 HUMSC-NC transplantation reduced Aβ deposition and solu
cortex and hippocampus in the mice. The staining was performed accordin
with a camera system connected to a fluorescence microscope (Olympus 1
staining. The plaque burden was calculated as the percentage of thioflavin
Plus 6 (Media Cybernetics) was used to analyze the images. (C, D) ELISA fo
brain tissue was homogenized, and soluble protein was extracted. Aβ ELISA
(n = 6 in each group). Data are presented as mean ± SEM; *P < 0.05; **P <by HUMSC-NC transplantation, we performed ELISA
to quantify soluble Aβ40 and Aβ42 levels in the mice.
We found that both Aβ40 and Aβ42 levels in the mice
treated with HUMSC-NCs were significantly decreased
compared with those in the mice treated with PBS
(Figure 4C, D). Our results suggest that HUMSC-NC
transplantation significantly reduces Aβ deposition in
the AD mice.
HUMSC-NC transplantation stimulates microglial
activation in AβPP/PS1 mice
We then further investigated the mechanism by which
HUMSC-NC transplantation reduces Aβ deposition.ble Aβ levels. (A) Thioflavin S staining for senile plaques of cerebral
g to the description in the Methods section. Images were captured
×71S1F-3, Japan). Scale bar, 200 μm. (B) Quantification of thioflavin S
S staining area over the total area (n = 6 in each group). Image Pro
r soluble Aβ40 (C) and Aβ42 (D) in the cortex and hippocampus. Mouse
kits (Invitrogen) was used to determine the levels of Aβ40 and Aβ42
0.01; HUMSC-NC-treated group versus PBS-treated group.
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plantation significantly increased the number of acti-
vated microglia in the cortex and hippocampus of the
mice compared with PBS injection (Figure 5A, B).
The Iba1 staining showed that the microglia in the
mice treated with HUMSC-NCs displayed an activated
microglial morphology characterized by large cell
body and thick processes (Figure 5A). The density of
the activated microglia reached the highest around
the plaques, corpus callosum, hippocampus, and cor-
tex area near the injection site (data not show). Mi-
croglial activation was not observed in the mice treated
either with HUMSCs or with PBS injection. These data
indicate that HUMSC-NC transplantation stimulates
microglial activation in AβPP/PS1 mice.Figure 5 HUMSC-NC transplantation increased microglial activation.
both the hippocampus and cortex. The staining was performed as descri
stained with rabbit anti-mouse Iba-1 IgG (1:500, Wako), and then visualized w
(B) Quantification of the staining images. Iba-1 burden was calculated as the
quantification was performed by using the software Image Pro Plus 6 (Media
**P < 0.01; HUMSC-NC-treated group versus PBS-treated group.HUMSC-NC transplantation induces alternative microglial
activation and modulates neuroinflammation
Activated microglia can be either neuroprotective or
neurodestructive, depending on the phase of activation.
Alternatively, activated microglia (M2-like microglia)
have been found to protect neurons by increasing Aβ
clearance and reducing neuroinflammation. Thus, we used
the following markers for M2-like microglia: Chitinase
3-like 3 (YM-1), arginase-1 (Arg-1), AMCase, mannose
receptors C type 1 (MRC1), found in inflammatory zone 1
(FIZZ1), and haptoglobin/hemoglobin scavenger receptor
(CD163) to examine whether the activated microglia
induced by HUMSC-NC transplantation were M2-like
microglia. Our qRT-PCR assay showed that the gene-
expression levels of YM-1, Arg-1, MRC1, FIZZ1, and(A) Immunofluorescence staining for microglia with anti-Iba1 in
bed in the Methods section. The processed tissue section was
ith FITC-conjugated secondary antibody. Scale bar represents 20 μm.
percentage of Iba-1-positive area over the total area. The image
Cybernetics). Data are presented as mean ± SEM. *P < 0.05;
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mice treated with HUMSC-NCs were increased sub-
stantially, compared with those in the mice treated with
PBS (Figure 6A). Our immunofluorescence staining also
demonstrated that AMCase expression was colocalized
with Iba-1expression in microglia (Figure 6B), indicating
that the activated microglia induced by HUMSC-NC
transplantation have M2-like microglial characteristics.
Our results suggest that HUMSC-NC transplantation
induces M2-like microglial activation in AD mice.Figure 6 HUMSC-NC transplantation induced M2-like microglial activa
YM-1, MRC1, FIZZ1, and CD163 in the cortex or hippocampus were determ
(n = 6 in each group). (B) Immunofluorescence staining for AMCase and Ib
mouse Iba-1 IgG (1:500; Wako) and goat anti-mouse AMCase IgG (1:200, Sa
used to visualize the staining. Scale bar represents 50 μm. (C) mRNA levels
measured with quantitative RT-PCR (n = 6 in each group). (D) Double immuno
area. (E) Double immunofluorescence staining for IL-4 and Iba-1 in the cortex
with different staining. Images were captured by a camera system connected
represents 20 μm. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; HUAβPPswe/PS1dE mice have significantly higher levels
of proinflammatory cytokines, including IL-1β, IL-6, and
TNF-α, than do wild-type mice [18]. Reducing these cy-
tokines has been shown to prevent neuronal dysfunction
in AD [26]. We examined whether the beneficial effects
of HUMSC-NC transplantation were associated with a
reduction of the proinflammatory factors IL-1β, TNF-α,
and IL-6. Our RT-PCR result showed that the mRNA
levels of IL-1β and TNF-α were significantly reduced in
the cortex and hippocampus of the mice treated withtion and modulated neuroinflammation. (A) mRNA levels of Arg-1,
ined by quantitative RT-PCR. GAPDH was used as the reference gene.
a-1. Tissue sections were processed and stained with rabbit anti
nta Cruz). FITC- or TRITC-conjugated secondary antibodies (1:200) were
of IL-4, TNF-α, IL-1β, and IL-6 in the cortex or hippocampus were
fluorescence staining for TNF-α and Iba-1 in the cortex and hippocampus
and hippocampus area. The images were merged from individual images
to the fluorescence microscope (Nikon Eclipse 90i LH-M100CB-1). Scale bar
MSC-NC-treated group versus PBS-treated group.
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with PBS (Figure 6C), whereas the IL-6 level was not
different between the two groups. M2-like microglial acti-
vation has been shown to be associated with upregulation
of the antiinflammatory cytokine, IL-4 [27]. Our RT-PCR
result showed that the mRNA level of IL-4 in the cortex
and hippocampus of the mice treated with HUMSC-NCs
was significantly increased compared with that of the
control (Figure 6C).
To determine further whether the downregulation of the
proinflammatory cytokine TNF-α and the upregulation of
the antiinflammatory cytokine IL-4 were related to the acti-
vated microglia in the mice treated with HUMSC-NCs, we
performed double immunofluorescence staining for TNF-α
and Iba-1, or IL-4 and Iba-1. Significant increase of IL-4
expression and decrease of TNF-α expression were detected
in the Iba-1-positive cells in the cortex and hippocampus
of the mice treated with HUMSC-NCs compared with
those in the control (Figure 6D, E). This result suggests
that M2-like microglial activation is associated with the
modulation of neuroinflammation in the AD mice.Figure 7 HUMSC-NC transplantation increased the expression of Aβ-d
(A) and IDE (B) in the cortex or hippocampus were determined with RT-PC
cortex and hippocampus of HUMSC-NC-treated mice. (C) Representative W
hippocampus: 100 μg of protein was load in each lane. Duplicate samples
Western blot for NEP (D) and IDE (E). The densitometry of NEP and IDE ba
percentage of the expressions of NEP and IDE in the HUMSC- or HUMSC-N
calculated. The scanned image of Western blot was analyzed with the softw
HUMSC-NC-treated group versus PBS-treated group.The expression of Aβ-degrading factors is stimulated by
HUMSC-NC transplantation
Neprilysin (NEP) and insulin-degrading enzyme (IDE) are
the most important Aβ-degrading enzymes. Our RT-PCR
result demonstrated that the mRNA levels of NEP and
IDE in the mice treated with HUMSC-NCs were signifi-
cantly higher than those in the mice treated with PBS
(Figure 7A, B). IDE protein level in both the cortex and
hippocampus was also significantly increased by HUMSC-
NC transplantation (Figure 7C, E), whereas NEP protein
level was significantly elevated in the hippocampus but
not in the cortex of the mice treated with HUMSC-NCs
(Figure 7C, D) compared with that in the control. Our re-
sults indicate that HUMSC-NC transplantation reduces
Aβ deposition in AD mice by increasing Aβ removal.
Discussion
In this study, we used D609 to induce HUMSCs to
differentiate into HUMSC-NCs and transplanted the
HUMSC-NCs into AβPP/PS1 mice. We found that
HUMSC-NC transplantation reduced Aβ depositionegrading enzymes NEP and IDE. (A, B) The mRNA levels of NEP
R. Both NEP and IDE mRNA levels were increased significantly in the
estern blots for NEP and IDE protein expression in the cortex or
of each group were loaded into the gel. (D, E) Quantification of the
nds were first normalized to the loading control β-actin. The
C-treated group relative to that in the PBS-treated group was then
are Image J. Data were presented as mean ± SEM. *P < 0.05,
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associated with activating M2-like microglia and upregu-
lating neuroprotective cytokines.
D609 has been shown to increase markedly the ex-
pression level and activity of molecules associated with
the oxidative state of MSCs, including reactive oxygen
species (ROS), NADPH oxidase, and Rb protein [28].
The possible mechanism underlying D609-induced neur-
onal differentiation of HUMSCs might be associated
with the changes of these molecules.
The mice were not provided immunosuppression.
HUMSCs have been found to be able to escape immune
surveillance, possibly because of the absence of the anti-
gen major histocompatibility complex II (MHC-II) and
the co-stimulatory surface antigens CD40, CD80, and
CD86 [29-31]. It has also been shown that neuron-like
cells differentiated from human MSCs do not express
CD40 and CD86 [32]. These findings suggest that both
HUMSCs and the neuron-like cells differentiated from
human MSCs might have low immunogenicity and
might be well tolerated in xenotransplantation without
immunosuppression. Consistent with our findings, a
number of studies have demonstrated that transplant-
ation of human MSCs or neuron-like cells differentiated
from MSCs without immunosuppression produces bene-
ficial effects in animal models of AD, Parkinson disease,
traumatic brain injury, and stroke [10,33-36].
The beneficial effects produced by HUMSC-NC trans-
plantation might not directly come from the HUMSC-
NCs, but instead could be indirect effects caused by the
transplanted cells. We found injected cells in the hippo-
campus and cortex of the mice 1 week after the trans-
plantation (data not shown); however, 1 month after the
transplantation, few transplanted cells were detected,
both in the mice treated with HUMSCs and in the mice
treated with HUMSC-NCs. Similar observations have
been reported by other research groups. Hong et al. [33]
and Parr et al. [37] showed that only small numbers
of transplanted stem cells or induced neuron-like cells
engraft into injured tissues, and only a few grafted
cells survive. It has been proposed that the beneficial
outcome of cell transplantation in neurodegenerative
diseases could result from the paracrine factors in-
duced by cell transplantation and be sustained by the
paracrine factors even after transplanted cells die
[7,38]. Our results supported such hypotheses. We
found that the expression of antiinflammatory cyto-
kine IL-4 was significantly increased by HUMSC-NC
transplantation, which could lead to the induction of
M2-like microglial activation and Aβ removal in the
AD mice.
NEP and IDE are the most important Aβ-degrading en-
zymes. We found that HUMSC-NC transplantation sig-
nificantly increased IDE and NEP expression in the ADmice. Deletion of the NEP or IDE gene in mice increases
cerebral Aβ accumulation, whereas overexpression of
NEP and IDE reduces Aβ levels [39-41]. Multiple studies
showed that microglia secretes IDE and NEP [8,42,43].
Antiinflammatory cytokine IL-4 has also been found to in-
crease IDE and NEP levels, both in vitro and in vivo
[44,45]. In our study, we observed both M2-like microglial
activation and upregulation of IL-4 expression in the mice
treated with HUMSC-NCs, which then could lead to the
increase of NEP and IDE expression. We observed an ele-
vation of both mRNA and protein levels of NEP and IDE
by HUMSC-NC transplantation. Our results suggest that
HUMSC-NC transplantation reduces Aβ deposit by ele-
vating Aβ degradation.
M2-like microglial activation is stimulated in an AD
mouse model when MSCs are transplanted into the mice
[8]. In our study, single intracerebral injection of neuron-
like cells differentiated from HUMSCs into a similar AD
mouse model also significantly promoted M2-like micro-
glial activation. M2-like microglia have been shown to play
protective roles in AD through the following three mecha-
nisms: promoting Aβ clearance by directly secreting en-
zymes, phagocytizing Aβ, and secreting neuroprotective
cytokines [8,46-48].
The mechanism underlying M2-like microglial activa-
tion by cell transplantation remains unclear. It could be an
indirect effect from transplanted cells. We proposed that
D609-induced neuron-like cells could stimulate the secre-
tion of some bioactive paracrine factors, which then pro-
mote M2-like microglial activation. It has also been shown
that M2-like microglia can be recruited from bone mar-
row in an AD mouse model [7,49,50]. Thus, in our study,
the source of M2-like microglia activated by HUMSC-NC
transplantation could be either from bone marrow rec-
ruitment or from local resting microglia that could be
activated into M2-like microglia by paracrine factors sti-
mulated by HUMSC-NC transplantation, such as IL-4.
Antiinflammatory cytokine IL-4 has been found to
promote M2-like microglial activation [51] and induces
Aβ removal both in vitro and in vivo [44,45,52]. We ob-
served an upregulation of IL-4 expression by HUMSC-
NC transplantation, and our immunofluorescence stain-
ing showed that IL-4 expression was markedly increased
in Iba-1-positive cells in particular. Our results suggest
that M2-like microglial activation in the mice treated
with HUMSC-NCs could be mediated by upregulation
of IL-4 expression.
Both our RT-PCR and immunocytochemistry stai-
ning results suggest that HUMSC-NC transplantation
downregulates the expression of proinflammatory cyto-
kines, including TNF-α and IL-1β. TNF-α, IL-6, and IL-1β
are markers for classic microglia (M1-like microglia).
These proinflammatory cytokines have been shown to
promote Aβ production and reduce Aβ removal in an AD
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can be inhibited by proinflammatory cytokines, such as
IL-1β, TNF-α, IFN-γ, MCP-1, and CD40L [54]. Thus, re-
ducing these proinflammatory cytokines could promote
Aβ clearance in AD. Our results suggest that HUMSC-
NC transplantation reduces the chronic inflammation
mediated by M1-like microglia and induces M2-like mi-
croglial activation to enhance Aβ removal, which conse-
quently results in cognitive improvement in the AD mice.
In our study, HUMSC transplantation did not produce
beneficial effects in the AD mice; although transplant-
ation of MSCs has been shown to rescue memory defi-
cits and reduce Aβ deposition in a similar AD mouse
model [8]. The inconsistent observation might be be-
cause different experimental procedures for cell trans-
plantation were used in the studies. In our study, we
performed single injections of HUMSCs into mice,
whereas in the studies of others, mice received double
or triple injections of MSCs. In addition, it has been
shown that a single injection of bone-marrow MSCs
does not promote M2-like microglial activation and fails
to improve the cognitive activity in an AD mouse model,
whereas multiple transplantations produce beneficial
effects [8]. We found that single transplantation of
HUMSC-NCs improved memory and reduced Aβ de-
position in the AD mice, which is consistent with
others’ observation that single transplantation of neuron-
like cells differentiated from MSCs produces beneficial
effects in neurodegenerative diseases and spinal cord in-
jury [9-11].Conclusion
Our study demonstrated that transplantation of neuron-
like cells differentiated from MSCs isolated from human
Wharton jelly of the umbilical cord decreased Aβ depo-
sition and improved memory in AβPP/PS1 transgenic
mice by a mechanism associated with activating M2-like
microglia and modulating neuroinflammation. Trans-
plantation of neuron-like cells differentiated from stem
cells might be a promising cell therapy for AD.Additional file
Additional file 1: Figure S1. Immunocytochemistry staining for GFAP
in HUMSC-NCs and positive control (astrocytes). Cells were fixed and
stained with rabbit anti-human GFAP IgG (1:200). Fluorescent dye
conjugated secondary antibody, goat anti-rabbit IgG-TRITC, was used to
visualize the cells. The images were captured by a camera system
connected to a fluorescence microscope (Olympus 1 × 71S1F-3).
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